These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918 [TBL] [Abstract][Full Text] [Related]
5. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744 [TBL] [Abstract][Full Text] [Related]
6. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658 [TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598 [TBL] [Abstract][Full Text] [Related]
8. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review. Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909 [TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104 [TBL] [Abstract][Full Text] [Related]
14. [New molecular approaches in dermatofibrosarcoma protuberans]. Kaya G Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363 [TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532 [TBL] [Abstract][Full Text] [Related]
18. Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case report. Bashir S; Tariq M; Aslam HM; Hashmi AS; Malik B; Amin A; Mumtaz S J Med Case Rep; 2015 Apr; 9():96. PubMed ID: 25924890 [TBL] [Abstract][Full Text] [Related]
19. Current treatment options in dermatofibrosarcoma protuberans. Lemm D; Mügge LO; Mentzel T; Höffken K J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737 [TBL] [Abstract][Full Text] [Related]